Smart Tumor-Targeting Peptides That Activate Only Where Cancer Is Present
Protease-activated CendR peptides targeting tenascin-C bind to the tumor receptor NRP-1 only after cleavage by the cancer enzyme uPA, reducing off-target accumulation in healthy tissues like lungs.
Quick Facts
What This Study Found
Two novel peptides (PL3uCendR and SKLG) bind tenascin-C constitutively but only activate NRP-1 binding after uPA cleavage, reducing off-target tissue accumulation while maintaining tumor penetration.
Key Numbers
PL3 peptide (AGRGRLVR) was modified for protease activation. Off-target lung accumulation was significantly reduced.
How They Did This
Rational design and uPA-treated phage library screening on recombinant NRP-1, validated with in vitro cleavage/binding/internalization assays and in vivo biodistribution in orthotopic glioblastoma mice.
Why This Research Matters
Off-target toxicity is a major challenge for peptide-drug conjugates and targeted nanoparticles. Protease-activated peptides that only engage their tumor-penetrating function in the tumor microenvironment could dramatically improve the therapeutic window of cancer nanomedicines.
The Bigger Picture
This study establishes a general technology platform for making any CendR tumor-penetrating peptide protease-dependent, potentially solving the off-target problem that has limited the clinical translation of tumor-homing peptides.
What This Study Doesn't Tell Us
Preclinical mouse data only; glioblastoma model may not generalize to all tumor types; uPA expression varies across cancers; peptide stability and pharmacokinetics in humans not established; no drug payload attached for therapeutic efficacy testing.
Questions This Raises
- ?How much does uPA-dependent activation improve the therapeutic index of peptide-drug conjugates?
- ?Can this technology be combined with existing approved nanoparticle therapies?
- ?Do all tumors express enough uPA to reliably activate these peptides?
Trust & Context
- Key Stat:
- uPA-activated peptides bind tumor receptor NRP-1 only in the cancer microenvironment
- Evidence Grade:
- Preliminary preclinical evidence demonstrating proof-of-concept for protease-activated tumor-penetrating peptides in glioblastoma mouse models.
- Study Age:
- Published in 2024, representing cutting-edge advances in smart peptide drug delivery design.
- Original Title:
- Protease-activated CendR peptides targeting tenascin-C: mitigating off-target tissue accumulation.
- Published In:
- Drug delivery and translational research, 14(10), 2945-2961 (2024)
- Authors:
- Tobi, Allan(2), Haugas, Maarja, Rabi, Kristina, Sethi, Jhalak, Põšnograjeva, Kristina, Paiste, Päärn, Jagomäe, Toomas, Pleiko, Karlis, Lingasamy, Prakash, Teesalu, Tambet
- Database ID:
- RPEP-09389
Evidence Hierarchy
Frequently Asked Questions
Why do cancer-targeting peptides sometimes harm healthy tissues?
Many tumor-targeting peptides bind to receptors like NRP-1 that are also present in healthy tissues, especially the lungs. This means the peptides — and any drugs attached to them — can accumulate where they're not wanted, causing side effects.
How do these new peptides solve the off-target problem?
They're designed with a built-in lock that only opens in the tumor environment. The cancer enzyme uPA acts as the key, cleaving the peptide to expose its NRP-1 binding site. In healthy tissues without uPA, the peptide remains locked and can't bind.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09389APA
Tobi, Allan; Haugas, Maarja; Rabi, Kristina; Sethi, Jhalak; Põšnograjeva, Kristina; Paiste, Päärn; Jagomäe, Toomas; Pleiko, Karlis; Lingasamy, Prakash; Teesalu, Tambet. (2024). Protease-activated CendR peptides targeting tenascin-C: mitigating off-target tissue accumulation.. Drug delivery and translational research, 14(10), 2945-2961. https://doi.org/10.1007/s13346-024-01670-2
MLA
Tobi, Allan, et al. "Protease-activated CendR peptides targeting tenascin-C: mitigating off-target tissue accumulation.." Drug delivery and translational research, 2024. https://doi.org/10.1007/s13346-024-01670-2
RethinkPeptides
RethinkPeptides Research Database. "Protease-activated CendR peptides targeting tenascin-C: miti..." RPEP-09389. Retrieved from https://rethinkpeptides.com/research/tobi-2024-proteaseactivated-cendr-peptides-targeting
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.